Maxim analyst Michael Okunewitch downgraded FibroBiologics (FBLG) to Hold from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens
- FibroBiologics Launches New At-The-Market Equity Offering
- FibroBiologics reports Q1 net loss roughly (5M)
- FibroBiologics Secures Nasdaq Listing Compliance, Under Monitoring
- FibroBiologics announces compliance with all Nasdaq listing requirements